Gsk

Thursday, 09 February 2023

Latest News for: gsk

Edit

Financial Results for the Year Ended December 31, 2022 (GSK - GlaxoSmithKline Pakistan Ltd)

Public Technologies 09 Feb 2023

) ... You can access the original document here ... Disclaimer. GSK - GlaxoSmithKline Pakistan Ltd.

Edit

Cytel and GSK Partner to Advance Clinical Trial Design with Solara

Nasdaq Globe Newswire 07 Feb 2023

GSK plans expansion of Solara clinical trial strategy platform to optimize design selection across therapeutic areas. GSK plans expansion of Solara clinical trial strategy platform to optimize design selection across therapeutic areas ... .

Edit

GSK's India unit posts 9% rise in Q3 profit as input costs slump

Reuters 07 Feb 2023

GSK plcFollow. BENGALURU, Feb 7 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd (GLAX.NS), the Indian unit of UK's GSK plc (GSK.L), reported a 9.5% rise in third-quarter profit on Tuesday, in line with analysts' estimates, as a sharp drop in input costs more than offset a revenue decline.

Edit

GSK, formerly GlaxoSmithKline, hiring at Lancaster County facility; here's why

Lancaster Online 06 Feb 2023

Drugmaker GSK says it plans to add about 65 employees by year’s end to the 300 already working at its Marietta campus ... .

Edit

GSK workers resume strike action as union admit dispute could drag on

Daily Record 06 Feb 2023

Unite chiefs say their members are determined to get 'what they are owed' in bonus payments row ... .

Edit

GSK announces results from 17-year retrospective study on US clinical trial diversity (GSK plc)

Public Technologies 06 Feb 2023

GSK plc (LSE/NYSE. GSK) today announced results from a retrospective study on clinical trial diversity, investigating the historical representation of US-based participants in GSK clinical trials. The study looked at clinical trial demographic data from 495 GSK and ViiV clinical trials involving US-based participants from the period 2002 to 2019.

Edit

Global Therapeutic Monoclonal Antibodies Market Research Report 2022 Featuring Eli Lily and Co, GSK, Roche, Astra Zeneca, Bayer, Amgen, Johnson & Johnson, Pfizer, Novartis, Merck & Co.

PR Newswire 06 Feb 2023

The companies analysed in the report include Eli Lily and Co GSK plc Roche Astra Zenca plc Bayer Amgen Johnson & Johnson Pfizer Novartis Merck & Co.

Edit

GSK's Anemia Drug For Dialysis Patients Gets FDA Backing

MENA FN 02 Feb 2023

(MENAFN - The Peninsula) Bloomberg GSK Plc's anemia pill was cleared by US regulators for dialysis patients, adding a potential blockbuster to the drugmaker's stable of new medicines. The drug, ... .

Edit

Board Meeting - 4th Quarter 2022 on 9 February 2023 (GSK - GlaxoSmithKline Pakistan Ltd)

Public Technologies 02 Feb 2023

) ... You can access the original document here ... Disclaimer. GSK - GlaxoSmithKline Pakistan Ltd.

Edit

U.S. FDA approves GSK's anemia drug for patients on dialysis

Reuters 02 Feb 2023

Food and Drug Administration (FDA) on Wednesday approved GSK Plc's (GSK.L) drug as the first oral treatment for anemia caused by chronic kidney disease in adults who have been on dialysis for at least four months ... GSK gives few clues on plans to replenish medicine cabinet, article with image.

Edit

GSK gives few clues on plans to replenish medicine cabinet

Yahoo Daily News 02 Feb 2023

LONDON (Reuters) -GSK chief executive Emma Walmsley on Wednesday made replenishing the drugmaker's pipeline of vaccines and therapies her number-one priority ... GSK largely missed out on the lucrative market for COVID-19 vaccines, but has had a string of strong quarters after years of underperformance relative to its peers.

Edit

FY 2022 results transcript (GSK plc)

Public Technologies 02 Feb 2023

The presentation was sent to our distribution list by email earlier today and you can also find details at GSK.com ... For today we are presenting continuing operations for GSK ... 2022 was a landmark year for GSK ... GSK plc published this content on 02 February 2023 and is solely responsible for the information contained therein.

Edit

GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations (GSK plc)

Public Technologies 01 Feb 2023

) Highlights. Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines. Sales of £29.3 billion +19% AER, +13% CER ... No change to expected dividend from GSK of 56.5p/share for 2023 ... Disclaimer. GSK plc published this content on 01 February 2023 and is solely responsible for the information contained therein.

Edit

FTSE 100 Live: Vodafone revenues fall in Europe, GSK profits rise

London Evening Standard 01 Feb 2023

Vodafone boss Margherita Della Valle stuck by the company’s full-year profits guidance today but said a decline in revenues in Europe showed “we can do better” ... .

Edit